This underscores the need for rigorously designed laboratory, animal, and clinical studies to elucidate the mechanism of action of these agents and to establish their efficacy and, more importantly, their safety
Robert SA, Rohana AG, Shah SA, Chinna K, Wan WN, Mohamud, Kamaruddin NA (2015) Improvement in binge-eating in non-diabetic obese individuals after 3 months of treatment with liraglutidea pilot study
Target-site resistance GluCl and complexin Two of the 18 included studies assessed target-site resistance, while the remaining studies assessed mechanisms of metabolic resistance or changes to efflux pump expression (Amanzougaghene et al
J Biomater Sci Polym Ed , 2008, 19(8): 969-988.[Crossref] 12
Ramaswamy Sharma, [email protected] These authors share first authorship Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
More research is needed, but the findings suggest that semaglutide and, perhaps other GLP-1 agonists, hold promise for helping people with MASH and highlight yet another potential benefit from this type of drug